Hepatitis A - Pipeline Insight, 2024

Hepatitis A - Pipeline Insight, 2024

DelveInsight’s, “Hepatitis A - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hepatitis A pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hepatitis A Understanding

Hepatitis A: Overview

Hepatitis A is caused by a virus resulting from an acute inflammation of the liver; it is the most common form of all viral hepatitis. It is encountered frequently in the most disadvantaged geographical regions. Generally, this inflammation is a result of a lack of safe water, and poor sanitation and hygiene. It is encountered frequently in urban areas but the incidence rates differ according to geographical regions and socio-economic levels. Despite progress in sanitation and hygiene, hepatitis A occurs sporadically and in epidemics worldwide, with a tendency for cyclic recurrences. The disease can lead to significant economic and social consequences in communities. The impact on food establishments identified with the virus, and local productivity in general, can be substantial.

""Hepatitis A - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis A pipeline landscape is provided which includes the disease overview and Hepatitis A treatment guidelines. The assessment part of the report embraces, in depth Hepatitis A commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis A collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis A R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis A.

Hepatitis A Emerging Drugs Chapters

This segment of the Hepatitis A report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatitis A Emerging Drugs

• Inactivated Hepatitis A Vaccine: Biological E Limited

Biological E Limited is developing an Inactivated Hepatitis A Vaccine. The vaccine is currently in Phase III stage of clinical trial evaluation.

• Hepatitis A vaccine inactivated: Indian Immunologicals

Inactivated hepatitis A vaccine is being developed by Indian Immunologicals for prevention of Hepatitis A infection. The vaccine is currently in Phase II/III stage of clinical trial evaluation.

Further product details are provided in the report……..

Hepatitis A: Therapeutic Assessment

This segment of the report provides insights about the different Hepatitis A drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hepatitis A

There are approx. 3+ key companies which are developing the therapies for Hepatitis A. The companies which have their Hepatitis A drug candidates in the most advanced stage, i.e. phase III include, Biological E Limited.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Hepatitis A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatitis A: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis A therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis A drugs.

Hepatitis A Report Insights

• Hepatitis A Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hepatitis A Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hepatitis A drugs?
• How many Hepatitis A drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis A?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatitis A therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hepatitis A and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Boryung Pharmaceutical
• Cadila Healthcare
• Indian Immunologicals
• Biological E Limited

Key Products

• BR 8003
• HAV 1001
• Hepatitis A vaccine inactivated
• Inactivated Hepatitis A Vaccine - Biological E